Contemporary Management ofStaphylococcus aureusBacteremia—Controversies in Clinical Practice

Abstract

Staphylococcus aureus bacteremia (SAB) carries a high risk for excess morbidity and mortality. Despite its prevalence, significant practice variation continues to permeate clinical management of this syndrome. Since the publication of the 2011 Infectious Diseases Society of America (IDSA) guidelines on management of methicillin-resistant Staphylococcus aureus infections, the field of SAB has evolved with the emergence of newer diagnostic strategies and therapeutic options. In this review, we seek to provide a comprehensive overview of the evaluation and management of SAB, with special focus on areas where the highest level of evidence is lacking to inform best practices.

Adherence to and clinical utility of “Quality Indicators” for Staphylococcus aureus bacteremia; a retrospective, multicenter study

“…Patients with SAB often have complications such as abscesses that generally form in the bone, joints, and muscles, as well as intravascular infections, such as infective endocarditis (IE). Thus, multidisciplinary management, including appropriate drainage/surgery and antibiotic treatment, is essential for patients with SAB [2][3][4][5]. Patients with persistent or complicated SAB in particular are at a greater risk of disseminated infections and higher mortality [6,7], and su cient therapeutic approaches are important to prevent recurrence and improve the prognosis of such patients [8,9].…”